Moderna Recovers From 10% Dive, But Muted Expectations Haunt Cancer Vaccine
Moderna stock yo-yoed Monday on more muted expectations for its Merck-partnered cancer vaccine, INT.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo